New Jersey's Medical Weight Loss for Life
New Jersey's Medical Weight Loss for Life · 223 Old Hook Road · Westwood, NJ 07675
5.0· 38 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
About this practice
New Jersey's Medical Weight Loss for Life is a medical weight-loss clinic in Westwood, New Jersey. Its website describes starting with a consultation that reviews past weight-management efforts and builds a customized plan, and says there are no monthly membership fees, contracts, annual fees or hidden costs. The listing includes semaglutide. On Google it holds a 5.0-star rating across 38 reviews dating back to 2023, with 5 posted in the past year. Reviewers most often mention the providers' knowledge and results, with 18 and 17 reviews respectively, and 12 mention the staff.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-06-24. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 38 Google reviews. Of the 38 reviews we analyzed, 38 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Weight-loss results17 reviews
- Knowledgeable, professional providers16 reviews
- Friendly, helpful staff12 reviews
- Clean, comfortable office9 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Grant★★★★★2026-06-24A life changing opportunity to feel healthier and more comfortable! Thank you Paul for being so helpful
mary m.★★★★★2026-06-23My experience was wonderful Donna was professional, calm and went Above and beyond to explain things
A★★★★★2026-05-29Unbelievable experience with Paul and the team. I was able to quickly get advice, feel comfortable, get the support I needed, and reach my personal health goals. I am very happy with the experience and would come back any time. Definitely recommend!!
SOCCERMAN925 *.★★★★★2026-05-29Great experience! We worked with Donna and Paul and could not ask for a better outcome. The process was very seamless and tailored to our individual goals and health needs. Also, best price I’ve seen!
Training Y.★★★★★2025-11-06Amazing weight loss center! The staff is kind, supportive, and really knows what they’re doing. I’ve lost weight, gained confidence, and finally feel healthy again. Highly recommend!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs